Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Bonus Article Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Article Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two smaller biotech companies are benefiting from strong share-price momentum thanks to their leading oncology medicines. Beyond offering therapeutic promise, these drugs could help the firms move beyond penny-stock (or otherwise unstable) status and toward longer-term stability and profitability. That said, both remain typical high-risk biotech investments with material challenges—and the potential for outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle I Met Elon Musk "Face-to-Face" During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally. As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date: March 26, 2026. Circle it on your calendar. I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade. Click Here to See how to Get Your "SpaceX Access Code" Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) gains, which have more than doubled shares so far. Still, with a consensus price target of $8.88, Wall Street suggests there may be more upside—about 71% from current levels. The main catalyst for Iovance's move is its lead product, Amtagvi, a T-cell immunotherapy for certain forms of melanoma. Amtagvi gained U.S. approval for melanoma in 2024 and has built momentum in sales, with additional approvals likely in the E.U., U.K., and elsewhere. When administered alongside Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in U.S. peak sales. Amtagvi's broader potential may extend beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and is being explored in multiple other tumor types. Iovance's strong performance this year was also supported by its Q4 2025 earnings report, released in late February, which showed smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year-over-year. Iovance remains a penny stock and a relatively small (about $2 billion) biotech, and analysts remain cautious—roughly half of the dozen ratings are Hold or Sell. Risks are elevated: beyond the usual challenges smaller biotech firms face, Amtagvi's manufacturing model is a vulnerability. The therapy is personalized, costly and complex to produce, which could limit profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug While ImmunityBio Inc. (NASDAQ: IBRX) slipped about 20% in March, its year-to-date performance dwarfs rivals—IBRX shares are up nearly 300% in 2026 alone. Analysts have set a price target of $13.60, roughly 70% above the stock's current level even after the recent jump. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the E.U. regulator granted the drug conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva drove $113 million in sales last year—a roughly 700% year-over-year increase. Like Amtagvi, Anktiva is being explored for additional cancer indications, and ImmunityBio continues to investigate alternative uses. Despite the dramatic run-up over recent quarters, IBRX shares remain speculative and risky. IBRX reported a full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Still, Wall Street sentiment is somewhat more bullish here than for Iovance: six of seven analysts rate the stock a Buy or equivalent. | 
